Tagged with research,

Pharma As President of Biopharma Activities for Merck in France, Pierre-Henry Longeray reveals how France is the third ranked affiliate after the US and Germany for the Group; how the French culture of innovation is one of the main drivers of the business; and how Merck is shifting from a pharmaceutical…

Pharma Dr. Teresa Corona Vázquez, the general director of one of the leading neuroscience institutions in Latin America, details their most important research partnerships and achievements, notably with regards to neurodegenerative diseases, and her expectations of fostering a heightened research-based relationship with the pharmaceutical industry. What have been some of the…

Pharma The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how high quality products have led to rapid success. You have worked in pharma all of your life including for AstraZeneca,…

Pharma While the Italian clinical research community works to an excellent standard of quality, and is relatively competitive in terms of costs, regulatory differences with the rest of Europe pose significant challenges. Mariapia Cirenei and Stefano Marini, president of AICRO and EUCROF respectively, discuss these current challenges, and how the new…

Pharma While assessing patient perspectives in comprehensive drug and treatment analyses may sound like a contemporary issue, the Mapi Group has been a pioneer in the practice for over forty years. Mapi Chairman Bernard Jambon explains the importance of patient incorporation in drug and therapy evaluation and his ambitions to expand…

Pharma Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of the cluster over the last decade while underscoring the critical importance of transparency and collaboration between government, industry and academia.…

Pharma Raffaele Stefanelli discusses the challenges of the medtech industry in Italy, the contribution of the Italian research community to Boston Scientific globally, and innovative partnership models. Could you introduce yourself to our readers as you currently hold two positions within Boston Scientific: managing director of the affiliate as well as…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…

Pharma Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the coming years, and is investing in R&D projects including the development of an ophthalmic orphan drug. The Italian pharmaceutical industry…

Pharma Family-owned Laboratori Baldacci is something of a rare breed in an industry dominated by multinational players. The senior research manager discusses the history of the company as well as how it plans to leverage its portfolio of innovative products and internationalization to drive growth in future. Could you please provide…

Pharma The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of translational research and his ambitious plans for the next five years, in particular, his vision for Cancer Core Europe, positioned…

Pharma Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current international reach, Mr. Quentric shares his vision on the next chapter for the company. Can you start by introducing Iris Pharma…